Syn X Partners With Ortho-Clinical and Princeton BioMeditech
Syn X Pharma has entered an exclusive worldwide licensing and development agreement with Ortho-Clinical Diagnostics, a Johnson & Johnson company, to develop its Alzheimer’s disease technology into a diagnostic test. Moreover, Syn X, based in Toronto, and Princeton BioMeditech have signed a letter of intent granting Syn X rights to distribute PBM’s LifeSign diagnostic products in Canada. The agreement is expected to be completed within the next two months.
NCI and FDA Publish Prostate Protein Profiles
The NCI’s Lance Liotta and the FDA’s Emanuel Petricoin have made new progress in disease protein profiling: last week, they and their colleagues reported having found protein patterns in serum that help distinguish between prostate cancer and benign prostate conditions. The researchers analyzed serum proteins, by mass spectrometry, from 56 patients who had undergone biopsy and whose disease status was known and used software developed by Correlogic Systems of Bethesda, Md., to search for protein patterns associated with prostate cancer. These patterns were then used to predict prostate cancer in a separate group of patients. Ninety-five percent of prostate cancers and 78 percent of benign disease were correctly predicted. The results of the study, published in the Journal of the National Cancer Institute, might help decide whether men with marginally elevated PSA levels should undergo biopsy.
Agilent To Sell Millennium’s Mass Spec Software
Agilent Technologies has obtained a licence from Millennium Pharmaceuticals to exclusively develop and sell software based on Millennium’s SpectrumMill software. SpectrumMill is a package of mass spectrometry data analysis tools developed and used internally at Millennium. It includes database searching for both MS and MS/MS data, quantitative analysis through isotope labeling such as ICAT, and supports instruments from most major vendors. The agreement also provides Millennium with early access to Agilent’s products and chemistries for proteomics research.
SurroMed Gets NIH SBIR For Alzheimer’s Test
SurroMed of Mountain View, Calif., has been awarded an NIH SBIR grant to develop diagnostic tests for Alzheimer’s disease using its biomarker technology.